Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 13/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 13/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801933 | 0.86 | MAOB (0.44) | AKR1C3AKR1C2CREBBPMAOBHTR2A | |
| SCHEMBL27051723 | 0.82 | IDO1 (0.47) | HTR2A | |
| SCHEMBL641868 | 0.81 | CREBBP (0.64) | AKR1C3AKR1C2CREBBP | |
| SCHEMBL12799701 | 0.81 | MAOB (0.63) | MAOB | |
| SCHEMBL12799708 | 0.81 | MAOB (0.44) | CREBBPMAOB | |
| SCHEMBL2721752 | 0.80 | HPGD (0.55) | HTR2A | |
| SCHEMBL7566116 | 0.80 | PTGDR2 (0.63) | AKR1C3AKR1C2CREBBPAKR1B10AKR1B1 | |
| SCHEMBL13528549 | 0.80 | AKR1C3 (0.51) | AKR1C3AKR1C2CREBBPAKR1B10AKR1B1 | |
| SCHEMBL8160607 | 0.79 | TSHR (0.44) | MAOBHTR2A | |
| SCHEMBL6196393 | 0.79 | PTPN11 (0.57) | AKR1C3AKR1C2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105617-A1 | C-Terminal Attachment of Two Chemical Groups to Peptides | NOVO NORDISK HEALTH CARE AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100105617-A1 | C-Terminal Attachment of Two Chemical Groups to Peptides | NOVO NORDISK HEALTH CARE AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100105617-A1 | C-Terminal Attachment of Two Chemical Groups to Peptides | NOVO NORDISK HEALTH CARE AG (CH) | 2010-04-29 | — | — | US | disclosed |
| EP-2121725-A1 | C-TERMINAL ATTACHMENT OF TWO CHEMICAL GROUPS TO PEPTIDES | Novo Nordisk Health Care AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008098958-A1 | C-TERMINAL ATTACHMENT OF TWO CHEMICAL GROUPS TO PEPTIDES | NOVO NORDISK HEALTH CARE AG (DK) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008098958-A1 | C-TERMINAL ATTACHMENT OF TWO CHEMICAL GROUPS TO PEPTIDES | NOVO NORDISK HEALTH CARE AG (DK) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105617-A1 | C-Terminal Attachment of Two Chemical Groups to Peptides | PTMS, DNPEP, VIP | AKR1C3 3491/4885AKR1C2 4087/4885CREBBP 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.